Skip to main content
Psychopharmacology Bulletin All Volumes & Issues VOL 47 No. 4 Persisting Psychosocial Impairments...
ORIGINAL PRESENTATIONS

Persisting Psychosocial Impairments in Adults Being Treated with Medication for Attention Deficit/Hyperactivity Disorder

Psychopharmacology Bulletin 47(4) :8-17 , 2017/09/15

Abstract

Attention-deficit/hyperactivity disorder (ADHD) is a common neurobehavioral condition in childhood.1 Of the 3–10% of children diagnosed with ADHD, it is thought that approximately one- to two-thirds (1–6% of the general population) will continue to have ADHD symptoms in adult life.1 • According to the American Psychiatric Association’s Diagnostic and Statistical Manual, fifth edition (DSM-5), ADHD is characterized by a persistent pattern of inattention, hyperactivity, and impulsivity that interferes with functioning or development.2 • In general, adults diagnosed with ADHD have been shown to have more impairments related to their work/school and social lives than matched samples of adults without ADHD.3–8 These impairments are key components of the diagnosis of ADHD, according to the DSM-5.2 Symptoms necessary for this diagnosis include impairments in interpersonal communication, irritability/mood lability, and cognition (including attention, executive function, or memory).2 • Various scales and instruments, such as the Behavior Rating Inventory of Executive Function-Adult version (BRIEF-A) assessments or the Brown Attention-Deficit Disorder Scale (BADDS), have also been used to assess the impairments in functioning commonly associated with ADHD.9–11

Access This Article

Choose an access option below to view the full article.

Subscriber Access

If you or your institution has a subscription, log in to access this article.

Log In

Purchase Article

Buy single-article access with a one-time purchase.

$30.00
Add to Cart

How to Cite

Thomas E. Brown, Emuella Flood, Phillip Sarocco, Norman Atkins, Alexandra Khachatryan. Persisting Psychosocial Impairments in Adults Being Treated with Medication for Attention Deficit/Hyperactivity Disorder. Psychopharmacology Bulletin. 2017/09/15; 47(4):8-17.